Technical Articles: Reagent Chemistry, Synthesis & Bioscience Guides

FDA-approved & Passed Phase I Drug Library: Key FAQs

FDA-approved & Passed Phase I Drug Library is a curated, ready-to-use collection of clinically validated and investigational compounds designed to accelerate drug repurposing, target identification, and high-throughput phenotypic screening in academic and pharmaceutical research settings.

Product Name
FDA-approved & Passed Phase I Drug Library
SKU / Catalog Number
Lib412045
Selleck Reference Number
L3800
Library Composition
FDA-approved drugs and compounds that have passed Phase I clinical trials, representing clinically validated and investigational chemical matter
Primary Applications
Drug repurposing, high-throughput screening (HTS), target identification, and phenotypic assays
Supplier
Aladdin Scientific

What Is the FDA-approved & Passed Phase I Drug Library?

The FDA-approved & Passed Phase I Drug Library (Lib412045) is a specialized compound collection offered by Aladdin Scientific, also referenced under Selleck number L3800. It brings together two distinct but complementary compound classes: drugs that have received full approval from the U.S. Food and Drug Administration (FDA) for clinical use, and investigational compounds that have successfully completed Phase I clinical trials, thereby demonstrating an acceptable human safety profile.

By combining approved therapeutics with early-stage clinical candidates, this library provides researchers with chemically and pharmacologically diverse starting points for a wide range of discovery projects. Each compound has already been evaluated in humans to some degree, which substantially de-risks downstream translational studies compared with purely pre-clinical chemical matter.

What Are the Main Applications of This Library?

The FDA-approved & Passed Phase I Drug Library is well-suited to multiple research workflows:

  • Drug Repurposing: Because all compounds have documented human exposure data, they are ideal candidates for identifying new therapeutic indications. Repurposing screens can rapidly advance hits into clinical evaluation without the need for extensive de novo toxicology studies.
  • High-Throughput Screening (HTS): The library format supports automated, miniaturized assay platforms. Researchers can run cell-based or biochemical assays across the full collection to identify active hits against novel targets or disease models.
  • Target Identification and Validation: Screening with known bioactive compounds accelerates the correlation of phenotypic effects with specific molecular targets, aiding mechanism-of-action studies.
  • Phenotypic Assays: The clinical-stage compounds in the collection enable physiologically relevant phenotypic screening in cell lines, organoids, or primary cultures, with results more directly translatable to in vivo outcomes.
  • Combination and Synergy Studies: The chemical diversity of the library facilitates the exploration of drug-drug interactions and synergistic effects relevant to oncology, infectious disease, and other therapeutic areas.

How Should the Library Be Stored and Handled?

Proper storage and handling are essential to maintain the integrity and bioactivity of compounds in the FDA-approved & Passed Phase I Drug Library. The following general best practices apply to compound libraries of this type; researchers should always consult the product-specific documentation provided with the shipment for authoritative conditions:

  • Temperature: Most small-molecule compound libraries are stored at −20 °C (long-term) or 4 °C (short-term working stocks). Confirm exact temperature requirements in the accompanying Certificate of Analysis (CoA).
  • Solvent: Compounds are typically supplied pre-dissolved in DMSO at a defined stock concentration. Avoid repeated freeze-thaw cycles, which can cause precipitation or degradation.
  • Light and Humidity: Store vials protected from light and in a dry environment. Many bioactive compounds are photosensitive or hygroscopic.
  • Aliquoting: Prepare working aliquots from master stocks to minimize the number of freeze-thaw cycles experienced by the bulk supply.
  • Contamination Control: Use sterile, low-binding tips and plates when dispensing compounds to prevent cross-contamination and non-specific binding losses.

For compound-specific stability data, purity certificates, and solubility information, refer to the documentation supplied by Aladdin Scientific at the time of delivery.

How Do I Design a Screening Workflow with This Library?

A systematic approach maximizes the value of the FDA-approved & Passed Phase I Drug Library in discovery campaigns. A recommended general workflow is outlined below:

  1. Define the Assay: Select a robust, validated primary assay (biochemical, cell-based, or phenotypic) with an acceptable signal-to-background ratio. Calculate the Z′-factor during assay development to confirm suitability for HTS.
  2. Prepare Compound Plates: Dilute library stocks to the desired screening concentration (commonly 1–10 µM final in assay) in assay-compatible buffer or medium. Include positive and negative controls on every plate.
  3. Primary Screen: Screen all compounds at a single concentration. Identify primary hits based on a pre-defined activity threshold (e.g., ≥50% inhibition or activation).
  4. Confirmation and Dose-Response: Retest primary hits in triplicate and generate concentration-response curves (CRC) to determine IC₅₀ or EC₅₀ values and confirm reproducibility.
  5. Counter-Screening and Selectivity: Run counter-assays to eliminate assay artefacts (e.g., fluorescent compounds, aggregators) and assess selectivity against related targets.
  6. Hit Prioritization: Rank confirmed hits by potency, selectivity, known clinical safety data, and tractability for the intended indication.

Detailed protocol optimization, including DMSO tolerance and cell-density requirements, should be established empirically for each assay system.

How Can I Order and What Should I Know Before Purchasing?

The FDA-approved & Passed Phase I Drug Library (Lib412045) is available through Aladdin Scientific's standard ordering channels. Before placing an order, consider the following points:

  • Catalog Reference: Quote SKU Lib412045 (Selleck reference L3800) in all purchase requests to ensure accurate fulfillment.
  • Format and Size Options: Compound libraries may be available in different plate formats, volumes per well, and concentration options. Contact Aladdin Scientific's technical sales team to confirm available configurations and select the format that best fits your screening platform.
  • Lead Time: Library products may require additional preparation time compared with single compounds. Confirm current lead times with your Aladdin Scientific representative at the time of inquiry.
  • Documentation: Request a Certificate of Analysis (CoA), compound list with structures and CAS numbers, and solubility data sheets at the time of order to streamline your assay setup.
  • Shipping and Storage on Receipt: Libraries are typically shipped on dry ice. Upon receipt, transfer immediately to the recommended storage temperature and inspect for any damage or leakage before use.
  • Regulatory and Safety: Consult the Safety Data Sheets (SDS) for individual compounds before handling. Some compounds may be subject to controlled substance regulations depending on jurisdiction.

Frequently asked questions

What types of compounds are included in the FDA-approved & Passed Phase I Drug Library?

The library contains two classes of compounds: drugs that have received full FDA approval for clinical use, and investigational agents that have successfully completed Phase I clinical trials and therefore have documented human safety data. This combination provides chemical diversity spanning multiple therapeutic targets and disease areas.

What is the catalog number for the FDA-approved & Passed Phase I Drug Library, and is there a cross-reference number?

The Aladdin Scientific catalog number (SKU) is Lib412045. This product also carries the Selleck reference number L3800, which can be used as a cross-reference when searching scientific literature or comparing with other suppliers' listings.

Why should I use an FDA-approved and Phase I-tested compound library instead of a purely pre-clinical diversity library?

Compounds in the FDA-approved & Passed Phase I Drug Library have already demonstrated acceptable safety profiles in humans, significantly reducing the translational risk associated with identified hits. This makes them ideal for drug repurposing programs, where the goal is to reach clinical application rapidly with reduced regulatory hurdles. Additionally, their known pharmacology can help elucidate mechanism of action for newly identified biological activities.

In what solvent and format is the library typically supplied?

Compound libraries of this type are generally supplied as pre-dissolved DMSO solutions formatted in multi-well plates (e.g., 96-well or 384-well). Specific concentration, volume, and plate format details for Lib412045 should be confirmed with Aladdin Scientific at the time of inquiry, as options may vary.

Can the library be used for combination drug screening or synergy studies?

Yes. The chemical and pharmacological diversity of the FDA-approved & Passed Phase I Drug Library makes it suitable for combination screening strategies, including matrix-based synergy assays in oncology or infectious disease models. Researchers can pair library compounds with a standard-of-care agent or investigational molecule to identify synergistic or antagonistic interactions.

References

  1. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs database. FDA.gov.
  2. Selleck Chemicals. L3800 FDA-approved & Passed Phase I Drug Library product information.
  3. Pushpakom S, et al. Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery. 2019;18(1):41-58. doi:10.1038/nrd.2018.168

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.

Categories: Technical Articles: Reagent Chemistry, Synthesis & Bioscience Guides

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.

Cite this article

Aladdin Scientific. "FDA-approved & Passed Phase I Drug Library: Key FAQs" Aladdin Knowledge Base, updated 2026/11/19. https://www.aladdinsci.com/us_ja/faqs/fda-approved-passed-phase-i-drug-library-faqs-en.html

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.